|
US5736367A
(en)
*
|
1992-03-31 |
1998-04-07 |
Medimmune, Inc. |
Vectors and prokaryotes which autocatalytically delete antibiotic resistance
|
|
US5869305A
(en)
*
|
1992-12-04 |
1999-02-09 |
The University Of Pittsburgh |
Recombinant viral vector system
|
|
US5693531A
(en)
*
|
1993-11-24 |
1997-12-02 |
The United States Of America As Represented By The Department Of Health And Human Services |
Vector systems for the generation of adeno-associated virus particles
|
|
JPH10501686A
(ja)
|
1994-04-13 |
1998-02-17 |
ザ ロックフェラー ユニヴァーシティ |
神経系の細胞へのdnaのaav仲介送達
|
|
US5856152A
(en)
*
|
1994-10-28 |
1999-01-05 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV vector and methods of use therefor
|
|
US6924128B2
(en)
|
1994-12-06 |
2005-08-02 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant AAV vectors
|
|
WO1996017947A1
(en)
*
|
1994-12-06 |
1996-06-13 |
Targeted Genetics Corporation |
Packaging cell lines for generation of high titers of recombinant aav vectors
|
|
US6281010B1
(en)
|
1995-06-05 |
2001-08-28 |
The Trustees Of The University Of Pennsylvania |
Adenovirus gene therapy vehicle and cell line
|
|
US5756283A
(en)
*
|
1995-06-05 |
1998-05-26 |
The Trustees Of The University Of Pennsylvania |
Method for improved production of recombinant adeno-associated viruses for gene therapy
|
|
IL122206A0
(en)
*
|
1995-06-07 |
1998-04-05 |
Univ North Carolina |
Adeno-associated virus vectors for gene expression
|
|
US6093570A
(en)
*
|
1995-06-07 |
2000-07-25 |
The University Of North Carolina At Chapel Hill |
Helper virus-free AAV production
|
|
US6110456A
(en)
*
|
1995-06-07 |
2000-08-29 |
Yale University |
Oral delivery or adeno-associated viral vectors
|
|
AU719950B2
(en)
*
|
1995-06-07 |
2000-05-18 |
Yale University |
Oral delivery of adeno-associated viral vectors
|
|
AU763063B2
(en)
*
|
1995-06-07 |
2003-07-10 |
University Of North Carolina At Chapel Hill, The |
AAV transduction of myoblasts
|
|
US6040183A
(en)
*
|
1995-06-07 |
2000-03-21 |
University Of North Carloina At Chapel Hill |
Helper virus-free AAV production
|
|
US6143211A
(en)
|
1995-07-21 |
2000-11-07 |
Brown University Foundation |
Process for preparing microparticles through phase inversion phenomena
|
|
JPH11510142A
(ja)
|
1995-07-21 |
1999-09-07 |
ブラウン・ユニバーシティ・リサーチ・ファンデーション |
核酸負荷ポリマー微粒子を使用した遺伝子治療法
|
|
US6248720B1
(en)
|
1996-07-03 |
2001-06-19 |
Brown University Research Foundation |
Method for gene therapy using nucleic acid loaded polymeric microparticles
|
|
US6207457B1
(en)
|
1995-09-08 |
2001-03-27 |
Avigen, Inc. |
Targeted nucleotide sequence delivery and integration system
|
|
US6162796A
(en)
*
|
1995-09-27 |
2000-12-19 |
The Rockefeller University |
Method for transferring genes to the heart using AAV vectors
|
|
US5962313A
(en)
*
|
1996-01-18 |
1999-10-05 |
Avigen, Inc. |
Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
|
|
US5858351A
(en)
|
1996-01-18 |
1999-01-12 |
Avigen, Inc. |
Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
|
|
US5846528A
(en)
|
1996-01-18 |
1998-12-08 |
Avigen, Inc. |
Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
|
|
DE19608753C1
(de)
*
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
|
WO1997038723A1
(en)
*
|
1996-04-16 |
1997-10-23 |
Immusol Incorporated |
Targeted viral vectors
|
|
US5866552A
(en)
*
|
1996-09-06 |
1999-02-02 |
The Trustees Of The University Of Pennsylvania |
Method for expressing a gene in the absence of an immune response
|
|
US20020037867A1
(en)
*
|
1999-02-26 |
2002-03-28 |
James M. Wilson |
Method for recombinant adeno-associated virus-directed gene therapy
|
|
CA2264482A1
(en)
*
|
1996-09-06 |
1998-03-12 |
The Trustees Of The University Of Pennsylvania |
An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
|
|
EP0933997A4
(de)
*
|
1996-09-06 |
2000-08-16 |
Chiron Corp |
Verfahren und zusammensetzungen für die leberspezifische verabreichung von therapeutischen molekülen unter verwendung rekombinanter aav vektoren
|
|
US6544523B1
(en)
*
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
|
CA2270285A1
(en)
|
1996-12-18 |
1998-06-25 |
Targeted Genetics Corporation |
Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors
|
|
EP0856585A1
(de)
|
1997-01-29 |
1998-08-05 |
Introgene B.V. |
Ein induzierbares Replications- und Expressionssystem
|
|
US6037177A
(en)
*
|
1997-08-08 |
2000-03-14 |
Cell Genesys, Inc. |
Method for increasing the efficiency of recombinant AAV production
|
|
US6251677B1
(en)
|
1997-08-25 |
2001-06-26 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
|
CA2995542A1
(en)
|
1997-09-05 |
1999-03-11 |
Genzyme Corporation |
Methods for generating high titer helper-free preparations of recombinant aav vectors
|
|
US6566118B1
(en)
|
1997-09-05 |
2003-05-20 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
|
US6995006B2
(en)
|
1997-09-05 |
2006-02-07 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
|
WO1999018227A1
(en)
*
|
1997-10-08 |
1999-04-15 |
Advanced Research And Technology Institute |
Chimeric parvovirus-based recombinant vector system that specifically targets the erythroid lineage
|
|
US6642051B1
(en)
|
1997-10-21 |
2003-11-04 |
Targeted Genetics Corporation |
Amplifiable adeno-associated virus(AAV) packaging cassettes for the production of recombinant AAV vectors
|
|
BR9813930A
(pt)
|
1997-11-06 |
2006-12-19 |
Chiron Spa |
antìgeno neisserial
|
|
ATE446368T1
(de)
|
1998-01-14 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Antigene aus neisseria meningitidis
|
|
ATE490980T1
(de)
|
1998-03-19 |
2010-12-15 |
Human Genome Sciences |
Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
|
|
MX343752B
(es)
|
1998-05-01 |
2016-11-22 |
Novartis Vaccines & Diagnostics Inc |
Antigenos de neisseria meningitidis y composiciones que los contienen.
|
|
EP1849872A1
(de)
*
|
1998-05-20 |
2007-10-31 |
University Of Iowa Research Foundation |
Adenoassoziierte Virusvektoren und ihre Verwendung
|
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
|
EP2942393A1
(de)
|
1998-09-04 |
2015-11-11 |
Genzyme Corporation |
Verfahren zur erzeugung helferfreier präparate mit hohem titer aus freigesetzten rekombinanten aav-vektoren
|
|
US6200560B1
(en)
|
1998-10-20 |
2001-03-13 |
Avigen, Inc. |
Adeno-associated virus vectors for expression of factor VIII by target cells
|
|
US6221349B1
(en)
|
1998-10-20 |
2001-04-24 |
Avigen, Inc. |
Adeno-associated vectors for expression of factor VIII by target cells
|
|
US6759237B1
(en)
*
|
1998-11-05 |
2004-07-06 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
|
|
EP1135468B1
(de)
|
1998-11-10 |
2010-01-06 |
University Of North Carolina At Chapel Hill |
Virusvektoren und verfahren für ihre herstellung und verabreichung.
|
|
US6387368B1
(en)
|
1999-02-08 |
2002-05-14 |
The Trustees Of The University Of Pennsylvania |
Hybrid adenovirus-AAV virus and methods of use thereof
|
|
US20040043488A1
(en)
*
|
1999-02-17 |
2004-03-04 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Adeno-associated viral gene-transfer vector system
|
|
US6893865B1
(en)
|
1999-04-28 |
2005-05-17 |
Targeted Genetics Corporation |
Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
|
|
NZ571167A
(en)
|
1999-04-30 |
2010-05-28 |
Novartis Vaccines & Diagnostic |
Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
|
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
|
EP1939300A1
(de)
|
1999-05-28 |
2008-07-02 |
Targeted Genetics Corporation |
Verfahren und Zusammensetzung zur Senkung des Spiegels des Tumornekrosefaktors (TNF) bei TNF-assoziierten Leiden
|
|
US6537540B1
(en)
*
|
1999-05-28 |
2003-03-25 |
Targeted Genetics Corporation |
Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
|
|
US7122335B1
(en)
|
1999-06-08 |
2006-10-17 |
University Of Iowa Research Foundation |
Compounds and methods to enhance rAAV transduction
|
|
JP4969002B2
(ja)
|
1999-06-08 |
2012-07-04 |
ユニバーシテイ・オブ・アイオワ・リサーチ・フアウンデーシヨン |
rAAV形質導入を増加するための化合物および方法
|
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
|
US6596535B1
(en)
*
|
1999-08-09 |
2003-07-22 |
Targeted Genetics Corporation |
Metabolically activated recombinant viral vectors and methods for the preparation and use
|
|
EP1916258B1
(de)
|
1999-08-09 |
2014-04-23 |
Targeted Genetics Corporation |
Erweiterte Expression einer einstämmigen, heterologen Nukleotidsequenz von rekombinanten viralen Vektoren durch Modellierung der Sequenz mit stammübergreifenden Basispaaren
|
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
|
US6544786B1
(en)
|
1999-10-15 |
2003-04-08 |
University Of Pittsburgh Of The Commonwealth Of Higher Education |
Method and vector for producing and transferring trans-spliced peptides
|
|
PT2275551E
(pt)
|
1999-10-29 |
2015-06-29 |
Novartis Vaccines & Diagnostic |
Péptidos antigénicos de neisseria
|
|
ES2588917T3
(es)
|
2000-01-17 |
2016-11-07 |
Glaxosmithkline Biologicals Sa |
Vacuna de VME suplementada contra meningococo
|
|
US6429001B1
(en)
|
2000-01-26 |
2002-08-06 |
Chiron Corporation |
Recombinant AAV packaging systems
|
|
US6926898B2
(en)
|
2000-04-12 |
2005-08-09 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7939087B2
(en)
|
2000-10-27 |
2011-05-10 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from Streptococcus groups A & B
|
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
|
JP2004536579A
(ja)
|
2001-04-13 |
2004-12-09 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
血管内皮増殖因子2
|
|
US8067156B2
(en)
*
|
2001-05-31 |
2011-11-29 |
The Rockefeller University |
Method for generating replication defective viral vectors that are helper free
|
|
US8241622B2
(en)
|
2001-07-13 |
2012-08-14 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences
|
|
WO2003013683A1
(en)
*
|
2001-08-08 |
2003-02-20 |
Brown University Research Foundation |
Methods for micronization of hydrophobic drugs
|
|
WO2003035687A1
(en)
*
|
2001-10-22 |
2003-05-01 |
Novartis Ag |
Nogo receptor homologues and their use
|
|
CN103589692B
(zh)
|
2001-11-13 |
2018-07-24 |
宾夕法尼亚大学托管会 |
检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
|
|
CA2469718A1
(en)
*
|
2001-12-10 |
2003-06-19 |
Spherics, Inc. |
Methods and products useful in the formation and isolation of microparticles
|
|
ES2386386T3
(es)
|
2001-12-12 |
2012-08-20 |
Novartis Vaccines And Diagnostics S.R.L. |
Inmunización contra Chlamydia trachomatis
|
|
EP1463805B1
(de)
|
2001-12-17 |
2014-10-22 |
The Trustees of The University of Pennsylvania |
Sequenzen des adeno-assoziierten virus (aav) serotyp 9, diese enthaltende vektoren und verwendungen dafür
|
|
DK2359869T3
(en)
|
2001-12-17 |
2019-04-15 |
Univ Pennsylvania |
Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
|
|
CA2841097A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin and g-csf fusion proteins
|
|
US20050222061A1
(en)
|
2002-04-18 |
2005-10-06 |
Schulte Ralf W |
Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
|
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
|
WO2004042024A2
(en)
|
2002-11-01 |
2004-05-21 |
The Trustees Of The University Of Pennsylvania |
COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA
|
|
ATE546528T1
(de)
|
2002-11-13 |
2012-03-15 |
Univ Jefferson |
Zusammensetzungen und verfahren zur diagnose und behandlung von krebs
|
|
JP2007524349A
(ja)
|
2003-01-16 |
2007-08-30 |
ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア |
ICAM−1のsiRNA阻害のための組成物及び方法
|
|
AU2004206250B8
(en)
*
|
2003-01-21 |
2009-09-17 |
Bristol-Myers Squibb Company |
Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
|
|
WO2004089423A2
(en)
|
2003-03-31 |
2004-10-21 |
University Of Iowa Research Foundation |
Pharmico-gene theraphy of epithelial sodium channel associated disoders
|
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
|
US20050019927A1
(en)
*
|
2003-07-13 |
2005-01-27 |
Markus Hildinger |
DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER
|
|
EP1668143B1
(de)
|
2003-09-30 |
2013-03-20 |
The Trustees of The University of Pennsylvania |
Claden und sequenzen von adeno-assoziiertem virus (aav), diese enthaltende vektoren sowie verwendungen dafür
|
|
EP1713938A2
(de)
|
2004-02-09 |
2006-10-25 |
Thomas Jefferson University |
Diagnose und behandlung von krebserkrankungen mit oder nahe mit krebs in zusammenhang stehenden chromosomalen merkmalen lokalisierter microrna
|
|
ES2423060T3
(es)
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
|
KR101222281B1
(ko)
|
2004-03-29 |
2013-01-28 |
가르파마 컴퍼니 리미티드 |
신규 갈렉틴 9 개변체 단백질 및 그 용도
|
|
WO2006012625A2
(en)
*
|
2004-07-22 |
2006-02-02 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Stat3 decoy oligonucleotides and uses therefor
|
|
EP1828390B1
(de)
*
|
2004-12-15 |
2012-06-13 |
The University Of North Carolina At Chapel Hill |
Chimäre vektoren
|
|
DE23193606T1
(de)
|
2005-04-07 |
2024-02-15 |
The Trustees Of The University Of Pennsylvania |
Verfahren zur erhöhung der funktion eines aav-vektors
|
|
US8481505B2
(en)
|
2005-09-12 |
2013-07-09 |
The Ohio State University Research Foundation |
Compositions and methods for the diagnosis and therapy of BCL2-associated cancers
|
|
AU2006337093B2
(en)
|
2005-12-22 |
2013-03-14 |
Opko Pharmaceuticals, Llc. |
Compositions and methods for regulating complement system
|
|
AU2007205234B2
(en)
|
2006-01-05 |
2012-07-12 |
The Ohio State University Research Foundation |
MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
|
|
EP2484782B1
(de)
|
2006-01-05 |
2015-11-18 |
The Ohio State University Research Foundation |
Verfahren und Zusammensetzungen auf Mikro-RNA-Basis zur Diagnose und Behandlung von soliden Krebs
|
|
WO2007081680A2
(en)
|
2006-01-05 |
2007-07-19 |
The Ohio State University Research Foundation |
Microrna expression abnormalities in pancreatic endocrine and acinar tumors
|
|
WO2007084773A2
(en)
*
|
2006-01-20 |
2007-07-26 |
University Of North Carolina At Chapel Hill |
Enhanced production of infectious parvovirus vectors in insect cells
|
|
EP2522748A1
(de)
|
2006-03-02 |
2012-11-14 |
The Ohio State University |
Mikro-RNA-Expressionsprofil im Zusammenhang mit Bauchspeicheldrüsenkrebs
|
|
ES2446362T3
(es)
|
2006-03-20 |
2014-03-07 |
The Ohio State University Research Foundation |
Huellas de microARN durante megacariocipoyesis humana
|
|
CA2647769C
(en)
|
2006-03-20 |
2015-05-26 |
Japan Science And Technology Agency |
Control of intracellular target molecule by ip3 receptor-binding protein
|
|
JP5704741B2
(ja)
|
2006-03-31 |
2015-04-22 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Eg5遺伝子発現の抑制のための組成物および方法
|
|
WO2007127919A2
(en)
|
2006-04-28 |
2007-11-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the jc virus
|
|
US7605251B2
(en)
|
2006-05-11 |
2009-10-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the PCSK9 gene
|
|
EP2392583A1
(de)
|
2006-05-19 |
2011-12-07 |
Alnylam Europe AG. |
RNAi-Modulation von AHA und therapeutische Verwendungen davon
|
|
US7888498B2
(en)
|
2006-05-22 |
2011-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
|
JP2009540011A
(ja)
|
2006-06-12 |
2009-11-19 |
エクセジェニックス、インク.ディー/ビー/エー オプコ ヘルス、インク. |
血管新生のsiRNA阻害のための組成物及び方法
|
|
CN101511373B
(zh)
|
2006-06-19 |
2015-12-09 |
阿斯克肋匹奥生物制药公司 |
用于基因治疗的修饰的因子ⅷ和因子ⅸ基因和载体
|
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
|
ES2425387T3
(es)
|
2006-07-13 |
2013-10-15 |
The Ohio State University Research Foundation |
Mir-106a para diagnosticar adenocarcinoma de colon de pronóstico de supervivencia pobre
|
|
PL2044199T3
(pl)
*
|
2006-07-25 |
2013-04-30 |
Celladon Corp |
Przedłużony, podawany z prądem krwi, nasierdziowy, wieńcowy wlew wektorów wirusowych na bazie wirusów towarzyszących adenowirusom, zawierający SERCA2a do terapii genowej
|
|
US7872118B2
(en)
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
|
US20090209478A1
(en)
|
2006-09-21 |
2009-08-20 |
Tomoko Nakayama |
Compositions and methods for inhibiting expression of the hamp gene
|
|
US8841436B2
(en)
|
2007-03-15 |
2014-09-23 |
University Hospitals Cleveland Medical Center |
Screening, diagnosing, treating and prognosis of pathophysiologic status by RNA regulation
|
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
|
JP5350360B2
(ja)
|
2007-03-29 |
2013-11-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
エボラ由来の遺伝子の発現を阻害するための組成物および方法
|
|
EP2319926B1
(de)
|
2007-07-05 |
2016-08-31 |
Arrowhead Research Corporation |
DSRNA zur Behandlung viraler Infektionen
|
|
WO2009012263A2
(en)
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Tissue-specific micrornas and compositions and uses thereof
|
|
EP2173911B1
(de)
|
2007-07-31 |
2014-06-18 |
The Ohio State University Research Foundation |
Verfahren zur methylierungsreversion mittels abzielen auf dnmt3a und dnmt3b
|
|
EP2653561B1
(de)
|
2007-08-03 |
2016-03-02 |
The Ohio State University Research Foundation |
Ultrakonservierte Bereiche zur Codierung von ncRNA
|
|
EP3028708A1
(de)
|
2007-08-22 |
2016-06-08 |
The Ohio State University Research Foundation |
Verfahren und zusammensetzungen zur induzierung von epha7-deregulierung und erk-phosphorlylierung bei humaner akuter leukämie
|
|
EP3138926A3
(de)
|
2007-09-06 |
2017-04-05 |
The Ohio State University Research Foundation |
Mirna-signaturen in menschlichem ovarialkarzinom
|
|
EP2212440A4
(de)
|
2007-10-11 |
2011-04-06 |
Univ Ohio State Res Found |
Verfahren und zusammensetzungen zur diagnose und behandlung von adenokarzinomen der speiseröhre
|
|
WO2009076400A2
(en)
|
2007-12-10 |
2009-06-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor vii gene
|
|
EP2244740A1
(de)
|
2008-02-19 |
2010-11-03 |
Celladon Corporation |
Zusammensetzungen zur verbesserten aufnahme von virusvektoren in das myokard
|
|
CN105267233B
(zh)
|
2008-03-05 |
2019-07-26 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因表达的组合物和方法
|
|
US9217155B2
(en)
*
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
EP2690175B1
(de)
|
2008-09-02 |
2016-12-28 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur kombinierten Hemmung der Expression eines mutierenden EGFR-Gens und IL-6
|
|
US8546554B2
(en)
|
2008-09-25 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
|
|
EP2937418B1
(de)
|
2008-10-20 |
2017-10-18 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression des Transthyretin
|
|
JP5832293B2
(ja)
|
2008-12-04 |
2015-12-16 |
オプコ ファーマシューティカルズ、エルエルシー |
血管新生促進vegfイソ型を選択的に抑制する組成物および方法
|
|
EP2373382B1
(de)
|
2008-12-10 |
2017-02-15 |
Alnylam Pharmaceuticals, Inc. |
Auf gnaq zielende dsrna-zusammensetzungen und verfahren zur unterdrückung der expression
|
|
EP2396343B1
(de)
|
2009-02-11 |
2017-05-17 |
The University of North Carolina At Chapel Hill |
Modifizierte virusvektoren sowie verfahren zu ihrer herstellung und verwendung
|
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
|
CA2754043A1
(en)
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
|
AU2010227419A1
(en)
|
2009-03-27 |
2011-10-20 |
Proyecto De Biomedicina Cima, S.L. |
Methods and compositions for the treatment of cirrhosis and liver fibrosis
|
|
DK2425000T3
(da)
|
2009-04-30 |
2019-05-13 |
Univ Pennsylvania |
Sammensætninger rettet mod ledende luftvejsceller omfattende konstrukter af adeno-associeret virus
|
|
SI3988660T1
(sl)
|
2009-05-02 |
2025-09-30 |
Genzyme Corporation |
Genska terapija za nevrodegenerativne motnje
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
US9029338B2
(en)
|
2009-08-14 |
2015-05-12 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
|
US20120244127A1
(en)
|
2009-10-01 |
2012-09-27 |
The Trustees Of The University Of Pennsylvania |
AAV Vectors Expressing SEC10 for Treating Kidney Damage
|
|
BR112012009801A8
(pt)
|
2009-10-30 |
2016-08-30 |
Cns Therapeutics Inc |
Polipeptídeo neurturina e variante de neurturina
|
|
EP2496607B1
(de)
|
2009-11-02 |
2017-09-27 |
The Regents of The University of California |
Gewölbte komplexe zur zytokinfreisetzung
|
|
JP2014503173A
(ja)
|
2009-11-05 |
2014-02-13 |
プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ |
制御された発現系
|
|
US8551781B2
(en)
|
2009-11-19 |
2013-10-08 |
The Regents Of The University Of California |
Vault complexes for facilitating biomolecule delivery
|
|
US8227444B2
(en)
|
2009-12-04 |
2012-07-24 |
Opko Ophthalmics, Llc |
Compositions and methods for inhibition of VEGF
|
|
WO2011084694A1
(en)
|
2009-12-17 |
2011-07-14 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Stabilized stat3 decoy oligonucleotides and uses therefor
|
|
US9169494B2
(en)
|
2010-01-12 |
2015-10-27 |
The University Of North Carolina At Chapel Hill |
Restrictive inverted terminal repeats for viral vectors
|
|
US20130281510A1
(en)
|
2010-03-29 |
2013-10-24 |
Kumamoto University |
siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
|
|
EP3578657B1
(de)
|
2010-04-06 |
2024-03-20 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der cd274/pd-l1-genexpression
|
|
CA2833912C
(en)
|
2010-04-23 |
2021-09-21 |
University Of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
DK2561073T3
(en)
|
2010-04-23 |
2016-12-12 |
Univ Massachusetts |
Aav vectors targeted to central nervous system and methods of use thereof
|
|
CA3050894C
(en)
|
2010-04-23 |
2022-10-18 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
PT2561078T
(pt)
|
2010-04-23 |
2018-12-03 |
Cold Spring Harbor Laboratory |
Sharn com uma conceção estrutural inovadora
|
|
EP3456827A3
(de)
|
2010-06-02 |
2019-05-08 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur behandlung von leberfibrose
|
|
JP2013539453A
(ja)
|
2010-07-09 |
2013-10-24 |
エクセリクシス, インク. |
癌の治療のためのキナーゼ阻害物質の組み合わせ
|
|
US9309534B2
(en)
|
2010-07-12 |
2016-04-12 |
Universidad Autonoma De Barcelona |
Gene therapy composition for use in diabetes treatment
|
|
EP3118316A1
(de)
|
2010-09-02 |
2017-01-18 |
Université de Mons |
Zur behandlung von fazioskapulohumeraler muskeldystrophie nützliche wirkstoffe
|
|
US9193973B2
(en)
|
2010-12-10 |
2015-11-24 |
Alynylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (EPO) production
|
|
WO2012079046A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
|
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
|
CA2826273C
(en)
|
2011-02-10 |
2021-11-02 |
The University Of North Carolina At Chapel Hill |
Viral vectors with modified transduction profiles and methods of making and using the same
|
|
CN103502458B
(zh)
|
2011-02-17 |
2016-11-16 |
宾夕法尼亚大学托管会 |
用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法
|
|
KR102104401B1
(ko)
|
2011-03-29 |
2020-04-27 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
|
|
US20140155469A1
(en)
|
2011-04-19 |
2014-06-05 |
The Research Foundation Of State University Of New York |
Adeno-associated-virus rep sequences, vectors and viruses
|
|
EP3699286A1
(de)
|
2011-04-20 |
2020-08-26 |
The Trustees of the University of Pennsylvania |
Dosierpläne und zusammensetzungen zur aav-vermittelten passiven immunisierung von luftbürtigen krankheitserregern
|
|
WO2012145624A2
(en)
|
2011-04-21 |
2012-10-26 |
University Of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
|
EP2714906A1
(de)
|
2011-06-01 |
2014-04-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur einstellung der expression von mitochondrialem genom durch microrna
|
|
CA2839896A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
|
CA2839573A1
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
|
EP2723756B1
(de)
|
2011-06-21 |
2020-03-11 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von apolipoprotein-c-iii (apoc3)-genen
|
|
EP2723351B1
(de)
|
2011-06-21 |
2018-02-14 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von protein-c (proc)-genen
|
|
US20140235693A1
(en)
|
2011-06-23 |
2014-08-21 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
|
JP2014526887A
(ja)
|
2011-08-01 |
2014-10-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
造血幹細胞移植の成功率を改善する方法
|
|
CA2852066A1
(en)
|
2011-10-14 |
2013-04-18 |
The Ohio State University |
Methods and materials related to ovarian cancer
|
|
EP2771482A1
(de)
|
2011-10-27 |
2014-09-03 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Verfahren zur behandlung und diagnose von arteriosklerose
|
|
EP2814514B1
(de)
|
2012-02-16 |
2017-09-13 |
Atyr Pharma, Inc. |
Histidyl-trna-synthetasen zur behandlung von autoimmun- und entzündungserkrankungen
|
|
WO2013152230A1
(en)
|
2012-04-04 |
2013-10-10 |
The Trustees Of Columbia University In The City Of New York |
Smooth muscle specific inhibition for anti-restenotic therapy
|
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
|
US9193971B2
(en)
|
2012-04-10 |
2015-11-24 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Methods for the treatment of nonalcoholic steatohepatitis
|
|
WO2013153139A1
(en)
|
2012-04-11 |
2013-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment and diagnosis of acute leukemia
|
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
|
US20150150821A1
(en)
|
2012-07-09 |
2015-06-04 |
The Regents Of The University Of California |
Vault Immunotherapy
|
|
CN105120901A
(zh)
|
2012-07-11 |
2015-12-02 |
宾夕法尼亚大学托管会 |
Rpgr x染色体连锁视网膜退化的aav介导的基因治疗
|
|
EP2692868A1
(de)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
|
|
PL2900686T3
(pl)
|
2012-09-28 |
2021-01-25 |
The University Of North Carolina At Chapel Hill |
Wektory aav ukierunkowane na oligodendrocyty
|
|
BR112015013105B1
(pt)
|
2012-12-05 |
2022-02-08 |
Alnylam Pharmaceuticals, Inc |
Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
|
|
WO2014120975A1
(en)
|
2013-02-01 |
2014-08-07 |
California Institute Of Technology |
Antibody-mediated immunocontraception
|
|
WO2014124282A1
(en)
|
2013-02-08 |
2014-08-14 |
The Trustees Of The University Of Pennsylvania |
Enhanced aav-mediated gene transfer for retinal therapies
|
|
US8957044B2
(en)
|
2013-03-01 |
2015-02-17 |
Wake Forest University Health Sciences |
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
|
|
BR112015023108A8
(pt)
|
2013-03-13 |
2018-01-23 |
Geneweave Biosciences Inc |
sistema de acondicionamento de célula bacteriana, método para acondicionamento de uma molécula de ácido nucléico repórter, composição, método para detectar uma presença ou uma ausência de uma célula bacteriana em uma amostra, vetor, método para detectar um transcrito alvo em uma célula, método para detectar a presença de uma célula bacteriana em uma amostra e kit.
|
|
PT2970974T
(pt)
|
2013-03-14 |
2017-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de componente do complemento c5 e métodos para a sua utilização
|
|
WO2014159546A1
(en)
|
2013-03-14 |
2014-10-02 |
Asklepios Biopharmaceutical, Inc. |
Modified soluble vegf receptor-1 genes and vectors for gene therapy
|
|
BR112015021036A2
(pt)
|
2013-03-15 |
2017-10-10 |
Univ Pennsylvania |
composições e métodos para tratar mps1
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
EP2978446B1
(de)
|
2013-03-27 |
2020-03-04 |
The General Hospital Corporation |
Anti-cd33 antikörper zur behandlung von morbus alzheimer
|
|
AU2014251099B2
(en)
|
2013-04-08 |
2019-01-17 |
The University Of Kansas |
Chimeric adeno-associated virus/ bocavirus parvovirus vector
|
|
US9719106B2
(en)
|
2013-04-29 |
2017-08-01 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
|
|
JP2016523835A
(ja)
|
2013-05-15 |
2016-08-12 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
|
|
AU2014268529C1
(en)
|
2013-05-22 |
2020-10-01 |
Alnylam Pharmaceuticals, Inc. |
TMPRSS6 iRNA compositions and methods of use thereof
|
|
TWI664187B
(zh)
|
2013-05-22 |
2019-07-01 |
阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
|
EP3071598B1
(de)
|
2013-05-29 |
2021-07-07 |
Vybion, Inc. |
Einkettige intrakörper zur modifizierung des huntingtin-mutanten-abbaus
|
|
HRP20210031T1
(hr)
|
2013-06-24 |
2021-05-14 |
Weidong, Xiao |
Pripravci i metode mutantskog faktora viii
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
EP3068889B1
(de)
|
2013-09-26 |
2019-04-17 |
Universitat Autònoma De Barcelona |
Gentherapiezusammensetzungen zur verwendung bei der vorbeugung und/oder behandlung von nicht alkoholbedingter fettleber
|
|
MX385871B
(es)
|
2013-10-02 |
2025-03-18 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen lect2.
|
|
WO2015051318A1
(en)
|
2013-10-04 |
2015-04-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the alas1 gene
|
|
EP3079727A1
(de)
|
2013-12-12 |
2016-10-19 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Verfahren zur vorbeugung und behandlung von diabetischer kardiomyopathie mithilfe von mir-424/322
|
|
WO2015089368A2
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
|
EP3105331B1
(de)
|
2014-02-11 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Ketohexokinase (khk)-irna-zusammensetzungen und verfahren zur verwendung davon
|
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
|
JP6756700B2
(ja)
|
2014-03-18 |
2020-09-16 |
ユニバーシティ オブ マサチューセッツ |
筋萎縮性側索硬化症を処置するためのrAAVベースの組成物および方法
|
|
US11555059B2
(en)
|
2014-04-25 |
2023-01-17 |
The Trustees Of The University Of Pennsylvania |
LDLR variants and their use in compositions for reducing cholesterol levels
|
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療serpinc1相關疾患之方法和組成物
|
|
SG11201609376SA
(en)
|
2014-05-22 |
2016-12-29 |
Alnylam Pharmaceuticals Inc |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
US9458464B2
(en)
|
2014-06-23 |
2016-10-04 |
The Johns Hopkins University |
Treatment of neuropathic pain
|
|
KR101946180B1
(ko)
|
2014-08-25 |
2019-02-08 |
지니위브 바이오사이언시스, 인코포레이티드 |
비-복제 형질도입 입자 및 형질도입 입자-기반 리포터 시스템
|
|
EA201790551A1
(ru)
|
2014-09-07 |
2017-07-31 |
Селекта Байосайенсиз, Инк. |
Способы и композиции для ослабления иммунных ответов к пропускающему экзон вирусному трансферному вектору
|
|
WO2016037931A1
(en)
|
2014-09-11 |
2016-03-17 |
Fundación Para La Investigación Médica Aplicada |
Nucleic acid constructs and expression vectors for gene therapy of acute porphyrias and other diseases
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
WO2016054557A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Novel high efficiency library-identified aav vectors
|
|
TWI864340B
(zh)
|
2014-10-10 |
2024-12-01 |
美商艾爾妮蘭製藥公司 |
用於抑制hao1(羥酸氧化酶1(乙醇酸鹽氧化酶))基因表現的組合物及方法
|
|
WO2016065001A1
(en)
|
2014-10-21 |
2016-04-28 |
University Of Massachusetts |
Recombinant aav variants and uses thereof
|
|
TWI769565B
(zh)
|
2014-11-10 |
2022-07-01 |
美商阿尼拉製藥公司 |
B型肝炎病毒(HBV)iRNA組成物及其用途方法
|
|
WO2016081444A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
|
AU2015349759B2
(en)
|
2014-11-21 |
2022-01-06 |
The University Of North Carolina At Chapel Hill |
Aav vectors targeted to the central nervous system
|
|
JP6754361B2
(ja)
|
2014-12-16 |
2020-09-09 |
ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ |
若年型バッテン病のための遺伝子療法
|
|
EP3242945B1
(de)
|
2015-01-07 |
2021-09-01 |
Universitat Autònoma de Barcelona |
Einzelvektor-genkonstrukt mit insulin- und glucokinasegenen
|
|
AU2016206624B2
(en)
|
2015-01-14 |
2020-08-06 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for targeted gene transfer
|
|
KR102554850B1
(ko)
|
2015-02-06 |
2023-07-13 |
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 |
최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도
|
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
|
EP3256170B1
(de)
|
2015-02-13 |
2020-09-23 |
University of Massachusetts |
Zusammensetzungen und verfahren zur transitorischen freisetzung von polypeptiden
|
|
JP2018510621A
(ja)
|
2015-02-13 |
2018-04-19 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
パタチン様ホスホリパーゼドメイン含有3(PNPLA3)iRNA組成物およびその使用方法
|
|
MX2017011615A
(es)
|
2015-03-10 |
2018-04-11 |
Univ Columbia |
Construcciones de vectores virales adeno-asociados de glut1 recombinantes y métodos relacionados para restablecer la expresión de glut1.
|
|
EP3285788B1
(de)
|
2015-04-23 |
2024-12-18 |
University of Massachusetts |
Modulation der transgenexpression eines aav-vektors
|
|
US11046955B2
(en)
|
2015-04-24 |
2021-06-29 |
University Of Massachusetts |
Modified AAV constructs and uses thereof
|
|
WO2016200543A2
(en)
|
2015-05-13 |
2016-12-15 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
|
|
AU2016260401B2
(en)
|
2015-05-14 |
2022-05-19 |
St. Jude Children's Research Hospital, Inc. |
Nucleic acid molecules containing spacers and methods of use thereof
|
|
KR20220082100A
(ko)
|
2015-05-15 |
2022-06-16 |
리젠츠 오브 더 유니버시티 오브 미네소타 |
중추 신경계로의 아데노-연관 치료적 전달
|
|
US10966414B2
(en)
|
2015-05-26 |
2021-04-06 |
California Institute Of Technology |
Population control using engineered translocations
|
|
EP3307316A1
(de)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
|
WO2017024198A1
(en)
|
2015-08-06 |
2017-02-09 |
The Trustees Of The University Of Pennsylvania |
Glp-1 and use thereof in compositions for treating metabolic diseases
|
|
HK1257024A1
(zh)
|
2015-08-31 |
2019-10-11 |
宾夕法尼亚大学 |
用於治疗伴侣动物的aav-epo
|
|
EP3359663A4
(de)
|
2015-09-24 |
2019-08-14 |
The Trustees of The University of Pennsylvania |
Zusammensetzung und verfahren zur behandlung einer komplementvermittelten erkrankung
|
|
IL314171A
(en)
|
2015-09-28 |
2024-09-01 |
Univ Florida |
Methods and compositions for antibody-evading virus vectors
|
|
WO2017062750A1
(en)
|
2015-10-09 |
2017-04-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating stargardt's disease and other ocular disorders
|
|
WO2017066579A1
(en)
|
2015-10-14 |
2017-04-20 |
Audentes Therapeutics, Inc. |
Nucleic acid molecules containing spacers and methods of use thereof
|
|
WO2017070516A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
EP3364997B1
(de)
|
2015-10-22 |
2024-01-17 |
University of Massachusetts |
Aspartoacylase gentherapie zur behandlung von morbus canavan
|
|
US10188750B1
(en)
|
2015-10-23 |
2019-01-29 |
University Of South Florida |
Self-replicating cell selective gene delivery compositions, methods, and uses thereof
|
|
SG10201912763QA
(en)
|
2015-11-05 |
2020-02-27 |
Bamboo Therapeutics Inc |
Modified friedreich ataxia genes and vectors for gene therapy
|
|
US12214054B2
(en)
|
2015-11-30 |
2025-02-04 |
Duke University |
Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
|
|
IL308717A
(en)
|
2015-12-07 |
2024-01-01 |
Genzyme Corp |
Methods and compositions for treating a serpinc1-associated disorder
|
|
EP4085934A1
(de)
|
2015-12-11 |
2022-11-09 |
The Trustees of The University of Pennsylvania |
Gentherapeutische behandlung der familiären hypercholesterinämie
|
|
CN109069668B
(zh)
|
2015-12-14 |
2023-04-18 |
宾夕法尼亚州大学信托人 |
用于眼病的基因疗法
|
|
US11124546B2
(en)
|
2015-12-14 |
2021-09-21 |
The University Of North Carolina At Chapel Hill |
Modified capsid proteins for enhanced delivery of parvovirus vectors
|
|
AU2016370590B2
(en)
|
2015-12-14 |
2023-11-02 |
The Trustees Of The University Of Pennsylvania |
Composition for treatment of Crigler-Najjar syndrome
|
|
SG10201912935WA
(en)
*
|
2015-12-15 |
2020-02-27 |
Genzyme Corp |
Adeno-associated viral vectors for treating mucolipidosis type ii
|
|
KR20180088919A
(ko)
|
2015-12-24 |
2018-08-07 |
옥시레인 유케이 리미티드 |
인간 알파-n-아세틸갈락토사미니다아제 폴리펩티드
|
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
MA43968A
(fr)
|
2016-02-03 |
2018-12-12 |
Univ Pennsylvania |
Thérapie génique pour traiter la mucopolysaccharidose de type i
|
|
HRP20231451T1
(hr)
|
2016-02-05 |
2024-03-01 |
Emory University |
Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu
|
|
WO2017139381A1
(en)
|
2016-02-08 |
2017-08-17 |
University Of Iowa Research Foundation |
Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
|
|
CA3012344A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
AU2017221441A1
(en)
|
2016-02-17 |
2018-10-04 |
Children's Medical Center Corporation |
FFA1 (GPR40) as a therapeutic target for neural angiogenesis diseases or disorders
|
|
CN108697774A
(zh)
|
2016-02-22 |
2018-10-23 |
北卡罗来纳大学教堂山分校 |
治疗mps i-相关失明的aav-idua载体
|
|
WO2017155973A1
(en)
|
2016-03-07 |
2017-09-14 |
University Of Iowa Research Foundation |
Aav-mediated expression using a synthetic promoter and enhancer
|
|
EP3440210A4
(de)
|
2016-04-05 |
2019-11-27 |
University of Massachusetts |
Zusammensetzungen und verfahren zur selektiven hemmung der expression des grainyhead-like-proteins
|
|
EP3443081A4
(de)
|
2016-04-13 |
2019-10-30 |
Duke University |
Crispr/cas9-basierte repressoren zur in-vivo-ausschaltung von gen-targets und verfahren zur verwendung
|
|
US11773410B2
(en)
|
2016-04-13 |
2023-10-03 |
University Of Massachusetts |
Repairing compound heterozygous recessive mutations by allele exchange
|
|
CN109661470A
(zh)
|
2016-04-15 |
2019-04-19 |
宾夕法尼亚州大学信托人 |
新型aav8突变衣壳和含有其的组合物
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
EP3449250B1
(de)
|
2016-04-28 |
2020-11-04 |
Indiana University Research & Technology Corporation |
Verfahren und zusammensetzungen zur auflösung von komponenten einer viruspräparation
|
|
US12173305B2
(en)
|
2016-05-26 |
2024-12-24 |
University Of Iowa Research Foundation |
cis and trans requirements for terminal resolution of human bocavirus 1
|
|
EP3469083A1
(de)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung von paroxysmaler nächtlicher hämoglobinurie (pnh)
|
|
JP2019517274A
(ja)
|
2016-06-13 |
2019-06-24 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill |
最適化されたcln1遺伝子および発現カセットおよびそれらの使用
|
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
CA2971303C
(en)
|
2016-06-21 |
2026-03-03 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
|
US20190240353A1
(en)
|
2016-07-05 |
2019-08-08 |
University Of Massachusetts |
Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma
|
|
US11197936B2
(en)
|
2016-07-08 |
2021-12-14 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treatment of disorders and diseases involving RDH12
|
|
JP7490211B2
(ja)
|
2016-07-19 |
2024-05-27 |
デューク ユニバーシティ |
Cpf1に基づくゲノム編集の治療適用
|
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
AU2017301705A1
(en)
|
2016-07-26 |
2019-01-24 |
North Carolina State University |
Vector-mediated immune tolerance in the eye
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
KR20190075964A
(ko)
|
2016-10-13 |
2019-07-01 |
유니버시티 오브 매사추세츠 |
Aav 캡시드 설계
|
|
KR20240007715A
(ko)
|
2016-10-14 |
2024-01-16 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
|
IL309808B2
(en)
|
2016-11-15 |
2025-04-01 |
Univ Minnesota |
Method for improving neurological function in MPSI and MPSII and other neurological disorders
|
|
TWI865997B
(zh)
|
2016-12-16 |
2024-12-11 |
美商阿尼拉製藥公司 |
使用甲狀腺素運載蛋白(TTR)iRNA組成物於治療或預防TTR相關疾病之方法
|
|
JP2020506890A
(ja)
|
2017-01-07 |
2020-03-05 |
セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. |
合成ナノキャリアにカップリングした免疫抑制剤のパターン化された投与
|
|
US11142775B2
(en)
|
2017-01-13 |
2021-10-12 |
University Of Iowa Research Foundation |
Bocaparvovirus small noncoding RNA and uses thereof
|
|
EP3579858A4
(de)
|
2017-02-07 |
2020-12-23 |
The Regents of The University of California |
Gentherapie für haploinsuffizienz
|
|
JP2020510648A
(ja)
|
2017-02-20 |
2020-04-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
家族性高コレステロール血症を処置するための遺伝子治療
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
TW201837170A
(zh)
|
2017-02-28 |
2018-10-16 |
賓州大學委員會 |
新穎aav媒介的流感疫苗
|
|
RS65241B1
(sr)
|
2017-02-28 |
2024-03-29 |
Univ Pennsylvania |
Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
|
|
WO2018160849A1
(en)
|
2017-03-01 |
2018-09-07 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
WO2018170310A1
(en)
|
2017-03-15 |
2018-09-20 |
The University Of North Carolina At Chapel Hill |
Polyploid adeno-associated virus vectors and methods of making and using the same
|
|
EP3606544B1
(de)
|
2017-04-05 |
2025-06-04 |
University of Massachusetts |
Minigentherapie
|
|
ES2994451T3
(en)
|
2017-04-20 |
2025-01-24 |
Atyr Pharma Inc |
Compositions for treating lung inflammation
|
|
US11879133B2
(en)
|
2017-04-24 |
2024-01-23 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
AU2018264996A1
(en)
|
2017-05-09 |
2019-12-05 |
University Of Massachusetts |
Methods of treating Amyotrophic Lateral Sclerosis (ALS)
|
|
BR112019023303A2
(pt)
|
2017-05-11 |
2020-06-16 |
The Trustees Of The University Of Pennsylvania |
Terapia de gene para lipofuscinoses ceroides neuronais
|
|
US11958887B2
(en)
|
2017-05-17 |
2024-04-16 |
The General Hospital Corporation |
Gene therapy for tuberous sclerosis
|
|
KR102765034B1
(ko)
|
2017-05-24 |
2025-02-11 |
유니버시타트 아우토노마 데 바르셀로나 |
섬유아세포 성장 인자 21 (fgf21) 코딩 서열을 포함하는 바이러스 발현 컨스트럭트
|
|
US11793887B2
(en)
|
2017-05-31 |
2023-10-24 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
|
US11827898B2
(en)
|
2017-06-14 |
2023-11-28 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
CA3068328A1
(en)
|
2017-07-06 |
2019-01-10 |
The Trustees Of The University Of Pennsylvania |
Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
|
|
JP2020530442A
(ja)
|
2017-07-10 |
2020-10-22 |
ジェンザイム・コーポレーション |
血友病を有する対象の出血事象を処置するための方法および組成物
|
|
AU2018301829B2
(en)
|
2017-07-13 |
2024-08-01 |
Alnylam Pharmaceuticals, Inc. |
Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase) gene expression
|
|
EP3679148A4
(de)
*
|
2017-09-08 |
2021-06-09 |
Generation Bio Co. |
Lipidnanopartikelformulierungen von nichtviralen, capsidfreien dna-vektoren
|
|
US11668719B2
(en)
|
2017-09-20 |
2023-06-06 |
The Trustees Of Indiana University |
Methods for resolving lipoproteins with mass spectrometry
|
|
CN118006607A
(zh)
|
2017-09-22 |
2024-05-10 |
马萨诸塞大学 |
Sod1双表达载体及其用途
|
|
US12441998B2
(en)
|
2017-10-12 |
2025-10-14 |
The Trustees Of Columbia University In The City Of New York |
SLC2A1 lncRNA as a biologic and related treatments and methods
|
|
WO2019075360A1
(en)
|
2017-10-13 |
2019-04-18 |
Selecta Biosciences, Inc. |
METHODS AND COMPOSITIONS FOR MITIGATING ANTI-VECTOR VIRAL TRANSFER IGM RESPONSES
|
|
AU2018350700B2
(en)
|
2017-10-16 |
2025-04-24 |
VeonGen Therapeutics GmbH |
AAV vectors
|
|
CA3078971A1
(en)
|
2017-11-01 |
2019-05-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
|
RU2020118342A
(ru)
|
2017-11-07 |
2021-12-08 |
Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл |
Оптимизированные гены aga и экспрессионные кластеры и их применение
|
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
|
SG11202004980RA
(en)
|
2017-11-28 |
2020-06-29 |
Mirimus Inc |
METHODS OF GENETIC MEDIATED ENGINEERING OF RNAi MODELS
|
|
CA3086045A1
(en)
|
2017-12-19 |
2019-06-27 |
Akouos, Inc. |
Aav-mediated delivery of therapeutic antibodies to the inner ear
|
|
US11008602B2
(en)
|
2017-12-20 |
2021-05-18 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
|
US11232941B2
(en)
|
2018-01-12 |
2022-01-25 |
The Trustees Of Indiana University |
Electrostatic linear ion trap design for charge detection mass spectrometry
|
|
JP7569216B2
(ja)
|
2018-01-17 |
2024-10-17 |
アドリーナス セラピューティクス, インコーポレイテッド |
21-ヒドロキシラーゼ欠損症のためのアデノ随伴ウイルス遺伝子療法
|
|
US12509492B2
(en)
|
2018-01-19 |
2025-12-30 |
Duke University |
Genome engineering with CRISPR-Cas systems in eukaryotes
|
|
CA3092107A1
(en)
|
2018-02-28 |
2019-09-06 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for antibody-evading virus vectors
|
|
EP3758736B1
(de)
|
2018-03-02 |
2024-05-01 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Il-34 zur anwendung in einem verfahren zur behandlung von retinaler entzündung und neurodegeneration
|
|
MX2020009579A
(es)
*
|
2018-03-15 |
2020-11-09 |
Intergalactic Therapeutics Inc |
Vectores de adn sintetico y metodos de uso.
|
|
EP4169576A1
(de)
|
2018-03-23 |
2023-04-26 |
University of Massachusetts |
Gentherapeutika zur behandlung von knochenerkrankungen
|
|
BR112020020266A2
(pt)
|
2018-04-03 |
2021-01-19 |
Stridebio, Inc. |
Vetores de vírus com evasão de anticorpos
|
|
MX2020010465A
(es)
|
2018-04-03 |
2021-01-08 |
|
Vectores de virus para direccionamiento a tejidos oftalmicos.
|
|
CA3095179A1
(en)
|
2018-04-03 |
2019-10-10 |
Stridebio, Inc. |
Antibody-evading virus vectors
|
|
WO2019200016A1
(en)
|
2018-04-10 |
2019-10-17 |
President And Fellows Of Harvard College |
Aav vectors encoding clarin-1 or gjb2 and uses thereof
|
|
BR112020021324A2
(pt)
|
2018-04-18 |
2021-01-19 |
The Trustees Of Columbia University In The City Of New York |
Terapia gênica para doenças causadas por pools de nucleotídeos em desequilíbrio incluindo síndromes de depleção do dna mitocondrial
|
|
CA3098448A1
(en)
|
2018-04-27 |
2019-10-31 |
University Of Massachusetts |
Aav capsids identified by in vivo library selection
|
|
KR102877876B1
(ko)
|
2018-05-08 |
2025-10-28 |
루트거스, 더 스테이트 유니버시티 오브 뉴 저지 |
Aav-상용성 라미닌-링커 중합 단백질
|
|
KR102742958B1
(ko)
|
2018-06-04 |
2024-12-16 |
더 트러스티즈 오브 인디애나 유니버시티 |
실시간 분석 및 신호 최적화를 통한 전하 검출 질량 분광분석법
|
|
WO2019236139A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Interface for transporting ions from an atmospheric pressure environment to a low pressure environment
|
|
US11227759B2
(en)
|
2018-06-04 |
2022-01-18 |
The Trustees Of Indiana University |
Ion trap array for high throughput charge detection mass spectrometry
|
|
WO2019236141A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Apparatus and method for capturing ions in an electrostatic linear ion trap
|
|
WO2019236143A1
(en)
|
2018-06-04 |
2019-12-12 |
The Trustees Of Indiana University |
Apparatus and method for calibrating or resetting a charge detector
|
|
WO2019236995A1
(en)
|
2018-06-08 |
2019-12-12 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
JP7428664B2
(ja)
|
2018-06-12 |
2024-02-06 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
合成肝臓指向性アデノ随伴ウイルスカプシドおよびその使用
|
|
CN112639110A
(zh)
*
|
2018-06-22 |
2021-04-09 |
阿斯克肋匹奥生物制药公司 |
用于基因递送以在细胞内持续存在的载体
|
|
IL313246B2
(en)
|
2018-06-28 |
2025-10-01 |
Univ North Carolina Chapel Hill |
Optimal cln5 expression genes and cassettes and their use
|
|
CN112771070A
(zh)
|
2018-07-16 |
2021-05-07 |
西莱克塔生物科技公司 |
Otc构建体和载体的方法和组合物
|
|
EP3823676A1
(de)
|
2018-07-16 |
2021-05-26 |
Selecta Biosciences, Inc. |
Verfahren und zusammensetzungen von mma-konstrukten und vektoren
|
|
IL280300B2
(en)
|
2018-08-10 |
2025-06-01 |
Univ North Carolina Chapel Hill |
Optimized cln7 genes and expression cassettes and their use
|
|
AR115960A1
(es)
|
2018-08-16 |
2021-03-17 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para inhibir la expresión del gen lect2
|
|
EP3833398A4
(de)
|
2018-09-21 |
2021-12-22 |
University of Connecticut |
Zusammensetzungen und verfahren zur wiederherstellung der paternalen ube3a-genexpression bei angelman-syndrom beim menschen
|
|
BR112021006074A2
(pt)
|
2018-11-05 |
2021-07-20 |
The University Of North Carolina At Chapel Hill |
genes e cassetes de expressão fig4 otimizados e seu uso
|
|
US11965172B2
(en)
|
2018-11-05 |
2024-04-23 |
California Institute Of Technology |
DNA sequence modification-based gene drive
|
|
CN113574632B
(zh)
|
2018-11-20 |
2024-07-30 |
印地安纳大学理事会 |
用于单粒子质谱分析的轨道阱
|
|
CN113166760A
(zh)
|
2018-11-23 |
2021-07-23 |
赛诺菲 |
用于抑制angptl8的新型rna组合物和方法
|
|
US12391947B2
(en)
|
2018-11-29 |
2025-08-19 |
University Of Massachusetts |
Modulation of SPTLC1 via recombinant adeno-associated vectors
|
|
AU2019392058B2
(en)
|
2018-12-03 |
2024-12-05 |
The Trustees Of Indiana University |
Apparatus and method for simultaneously analyzing multiple ions with an electrostatic linear ion trap
|
|
EP3898996A1
(de)
|
2018-12-20 |
2021-10-27 |
Vigeneron GmbH |
Optimiertes akzeptorspleissstellenmodul für biologische und biotechnologische anwendungen
|
|
EP3884057A4
(de)
|
2018-12-21 |
2022-09-07 |
The University of North Carolina at Chapel Hill |
Optimierte galc-gene und expressionskassetten sowie deren verwendung
|
|
CN113227404A
(zh)
|
2018-12-27 |
2021-08-06 |
豪夫迈·罗氏有限公司 |
用于检测鲍氏不动杆菌的非复制型转导颗粒和基于转导颗粒的报告系统
|
|
WO2020140007A1
(en)
|
2018-12-28 |
2020-07-02 |
University Of Rochester |
Gene therapy for best1 dominant mutations
|
|
US11572595B2
(en)
|
2018-12-31 |
2023-02-07 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
|
|
CA3131023A1
(en)
|
2019-02-22 |
2020-08-27 |
Michael R. Volkert |
Oxr1 gene therapy
|
|
CN113710693B
(zh)
|
2019-02-25 |
2025-07-15 |
马萨诸塞大学 |
Dna结合结构域反式激活因子及其用途
|
|
AU2020232692A1
(en)
|
2019-03-04 |
2021-09-30 |
The Trustees Of The University Of Pennsylvania |
Neuroprotective gene therapy targeting the AKT pathway
|
|
WO2020191241A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
|
CN113727992A
(zh)
|
2019-03-21 |
2021-11-30 |
斯特里迪比奥公司 |
重组腺相关病毒载体
|
|
US12553036B2
(en)
|
2019-04-12 |
2026-02-17 |
University Of Massachusetts |
GM3 synthase vectors and uses thereof
|
|
TWI887234B
(zh)
|
2019-04-14 |
2025-06-21 |
美國公爵大學 |
治療杜興氏(duchenne)肌肉失養症之大型突變熱點之aav載體介導之刪除
|
|
MX2021012681A
(es)
|
2019-04-15 |
2022-03-25 |
Spirovant Sciences Inc |
Composiciones y metodos para el tratamiento de la fibrosis quistica.
|
|
SG11202111353QA
(en)
|
2019-04-15 |
2021-11-29 |
Univ Iowa Res Found |
Methods and compositions for transgene expression
|
|
WO2020215010A1
(en)
|
2019-04-17 |
2020-10-22 |
Codiak Biosciences, Inc. |
Compositions of exosomes and aav
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
JP2022529917A
(ja)
|
2019-04-18 |
2022-06-27 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ガンの処置及び予後のための方法
|
|
WO2020219527A1
(en)
|
2019-04-23 |
2020-10-29 |
The Trustees Of Indiana University |
Identification of sample subspecies based on particle charge behavior under structural change-inducing sample conditions
|
|
EP3959324B1
(de)
|
2019-04-26 |
2025-09-17 |
President and Fellows of Harvard College |
Aav-vektoren zur codierung von mini-pcdh15 und verwendungen davon
|
|
CA3138525A1
(en)
|
2019-04-28 |
2020-11-05 |
Selecta Biosciences, Inc. |
Methods for treatment of subjects with preexisting immunity to viral transfer vectors
|
|
WO2020223232A1
(en)
|
2019-04-29 |
2020-11-05 |
The Trustees Of The University Of Pennsylvania |
Novel aav capsids and compositions containing same
|
|
EP3963073A4
(de)
|
2019-04-29 |
2023-01-25 |
The University of North Carolina at Chapel Hill |
Optimierte sumf1-gene und expressionskassetten sowie deren verwendung
|
|
US12390539B2
(en)
|
2019-05-20 |
2025-08-19 |
University Of Massachusetts |
Minigene therapy
|
|
EA202193214A1
(ru)
|
2019-05-22 |
2022-03-14 |
Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл |
Гены ube3a и кассеты экспрессии и их использование
|
|
CA3141863A1
(en)
|
2019-05-28 |
2020-12-03 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuated anti-viral transfer vector immune response
|
|
EP3987043A4
(de)
*
|
2019-06-21 |
2023-07-19 |
Asklepios Biopharmaceutical, Inc. |
Herstellung von vektoren unter verwendung des phagenreplikationsursprungs
|
|
WO2020261178A1
(en)
|
2019-06-27 |
2020-12-30 |
Pfizer Inc. |
Methods of treating duchenne muscular dystrophy using aav mini-dystrophin gene therapy
|
|
BR112021026866A2
(pt)
|
2019-07-02 |
2022-03-03 |
M6P Therapeutics |
Composições de vetor e métodos de seu uso para o tratamento de distúrbios do armazenamento lisossômico
|
|
ES2948620T3
(es)
|
2019-07-10 |
2023-09-14 |
Masonic Medical Res Laboratory |
Vgll4 con elemento regulador CIS de UCP-1 y método de uso del mismo
|
|
EP4007814A1
(de)
|
2019-07-26 |
2022-06-08 |
Akouos, Inc. |
Verfahren zur behandlung von hörverlust unter verwendung eines sekretierten zielproteins
|
|
CN115176011B
(zh)
|
2019-08-27 |
2025-11-11 |
赛诺菲 |
用于抑制pcsk9的组合物和方法
|
|
US20220290152A1
(en)
|
2019-09-03 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the lect2 gene
|
|
CN114555814A
(zh)
|
2019-09-13 |
2022-05-27 |
罗特格斯新泽西州立大学 |
Aav相容的层粘连蛋白-连接子聚合蛋白
|
|
WO2021055760A1
(en)
|
2019-09-18 |
2021-03-25 |
Intergalactic Therapeutics, Inc. |
Synthetic dna vectors and methods of use
|
|
US12112936B2
(en)
|
2019-09-25 |
2024-10-08 |
The Trustees Of Indiana University |
Apparatus and method for pulsed mode charge detection mass spectrometry
|
|
WO2021062012A1
(en)
|
2019-09-25 |
2021-04-01 |
Emory University |
Use of klk10 and engineered derivatizations thereof
|
|
US11834659B2
(en)
|
2019-09-26 |
2023-12-05 |
Massachusetts Institute Of Technology |
Trans-activated functional RNA by strand displacement and uses thereof
|
|
WO2021062096A1
(en)
|
2019-09-26 |
2021-04-01 |
Massachusetts Institute Of Technology |
Microrna-based logic gates and uses thereof
|
|
US12503699B2
(en)
|
2019-10-04 |
2025-12-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing UGT1a1 gene expression
|
|
US20230416776A1
(en)
|
2019-10-08 |
2023-12-28 |
Regents Of The University Of Minnesota |
Crispr-mediated human genome editing with vectors
|
|
JP7659325B2
(ja)
|
2019-10-10 |
2025-04-09 |
ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー |
粒子を識別、選択、および純化するためのシステムおよび方法
|
|
WO2021076656A1
(en)
|
2019-10-15 |
2021-04-22 |
University Of Massachusetts |
Rna editor-enhanced rna trans-splicing
|
|
CN114787180A
(zh)
|
2019-10-17 |
2022-07-22 |
斯特里迪比奥公司 |
用于治疗c型尼曼-匹克病的腺相关病毒载体
|
|
MX2022004353A
(es)
|
2019-10-17 |
2022-07-19 |
|
Casete de transferencia de aav.
|
|
US20230040920A1
(en)
|
2019-11-01 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
IL292865A
(en)
|
2019-11-13 |
2022-07-01 |
Alnylam Pharmaceuticals Inc |
Methods and preparations for the treatment of angiotensinogen-related disorder - (agt)
|
|
KR20220112283A
(ko)
|
2019-12-10 |
2022-08-10 |
다케다 야쿠힌 고교 가부시키가이샤 |
Hunter 질환 치료용 아데노-연합된 바이러스 벡터
|
|
JP7690209B2
(ja)
|
2019-12-18 |
2025-06-10 |
ザ・トラスティーズ・オブ・インディアナ・ユニバーシティー |
電荷測定装置を有する質量分析計
|
|
WO2021136752A1
(en)
|
2019-12-31 |
2021-07-08 |
F. Hoffmann-La Roche Ag |
Quantitative pcr screening of inducible prophage from bacterial isolates
|
|
US12665049B2
(en)
|
2020-01-17 |
2026-06-23 |
AskBio, Inc. |
Systems and methods for synthetic regulatory sequence design or production
|
|
WO2021146625A1
(en)
|
2020-01-17 |
2021-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Gene therapy for treatment of crx-autosomal dominant retinopathies
|
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
|
KR102923996B1
(ko)
|
2020-02-03 |
2026-02-05 |
더 트러스티즈 오브 인디애나 유니버시티 |
전하 검출 질량 분석법을 위한 신호들의 시간-도메인 분석
|
|
PH12022552080A1
(en)
|
2020-02-10 |
2024-02-12 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for silencing vegf-a expression
|
|
US20230089312A1
(en)
|
2020-02-25 |
2023-03-23 |
University Of Massachusetts |
Inducible single aav system and uses thereof
|
|
EP4100532B1
(de)
|
2020-03-23 |
2026-08-12 |
The University of North Carolina at Chapel Hill |
Aav-naglu-vektoren zur behandlung von mukopolysaccharidose iiib
|
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
BR112022019304A2
(pt)
|
2020-03-31 |
2022-12-06 |
Univ Massachusetts |
Variantes de capsídeo de aav e usos das mesmas
|
|
IL297121A
(en)
|
2020-04-06 |
2022-12-01 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for silencing myoc expression
|
|
AU2021251754A1
(en)
|
2020-04-07 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing SCN9A expression
|
|
WO2021216503A1
(en)
|
2020-04-20 |
2021-10-28 |
Christiana Care Health Services, Inc. |
Aav delivery system for lung cancer treatment
|
|
CA3177268A1
(en)
|
2020-05-05 |
2021-11-11 |
The University Of North Carolina At Chapel Hill |
Modified adeno-associated virus 5 capsids and uses thereof
|
|
TWI910162B
(zh)
|
2020-05-05 |
2026-01-01 |
美國公爵大學 |
跨物種相容腺相關病毒組合物及其使用方法
|
|
EP4165194A2
(de)
|
2020-05-13 |
2023-04-19 |
Akouos, Inc. |
Zusammensetzungen und verfahren zur behandlung von kcnq4-assoziiertem gehörverlust
|
|
KR20230041965A
(ko)
|
2020-05-13 |
2023-03-27 |
아카우오스, 인크. |
Slc26a4-연관 청력손실을 치료하기 위한 조성물 및 방법
|
|
WO2021237097A1
(en)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
US20230242941A1
(en)
|
2020-06-30 |
2023-08-03 |
Eric Yuen |
Methods and compositions for administering recombinant viral vectors
|
|
WO2022011099A1
(en)
|
2020-07-08 |
2022-01-13 |
Regents Of The University Of Minnesota |
Modified hexosaminidase and uses thereof
|
|
EP4700126A3
(de)
|
2020-07-23 |
2026-06-03 |
The University of North Carolina at Chapel Hill |
Optimierte slc13a5- gene und expressionskassetten sowie deren verwendung
|
|
WO2022036220A1
(en)
|
2020-08-14 |
2022-02-17 |
The Trustees Of The University Of Pennsylvania |
Novel aav capsids and compositions containing same
|
|
JP2023542614A
(ja)
|
2020-08-19 |
2023-10-11 |
サレプタ セラピューティクス, インコーポレイテッド |
レット症候群の治療のためのアデノ随伴ウイルスベクター
|
|
US20230372539A1
(en)
|
2020-08-24 |
2023-11-23 |
The Trustees Of The University Of Pennsylvania |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
|
US20230414787A1
(en)
|
2020-08-27 |
2023-12-28 |
University Of Iowa Research Foundation |
Gene knock-out for treatment of glaucoma
|
|
GB202013940D0
(en)
|
2020-09-04 |
2020-10-21 |
Synpromics Ltd |
Regulatory nucleic acid sequences
|
|
AU2021339003A1
(en)
|
2020-09-10 |
2023-02-09 |
Ludwig-Maximilians-Universität München |
Engineered AAV vectors
|
|
EP4217376A4
(de)
|
2020-09-24 |
2024-10-09 |
University of Massachusetts |
Für nf1 codierende aav-vektoren und verwendungen davon
|
|
US20230374542A1
(en)
|
2020-10-07 |
2023-11-23 |
Asklepios Biopharmaceutical, Inc. |
Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
|
|
JP2023544803A
(ja)
|
2020-10-07 |
2023-10-25 |
レジェンクスバイオ インコーポレーテッド |
Cln2疾患の眼症状に対する遺伝子療法
|
|
EP4229201A1
(de)
|
2020-10-16 |
2023-08-23 |
Sanofi |
Rna-zusammensetzungen und verfahren zur hemmung von lipoprotein(a)
|
|
US20230383294A1
(en)
|
2020-10-16 |
2023-11-30 |
Sanofi |
Novel rna compositions and methods for inhibiting angptl3
|
|
CA3198823A1
(en)
|
2020-10-21 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
|
MX2023005113A
(es)
|
2020-10-29 |
2023-08-04 |
Univ Pennsylvania |
Cápsides de aav y composiciones que las contienen.
|
|
WO2022119873A1
(en)
|
2020-12-01 |
2022-06-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
IL303317A
(en)
|
2020-12-01 |
2023-07-01 |
Akouos Inc |
ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
|
|
EP4255457A4
(de)
|
2020-12-03 |
2025-05-21 |
University of Massachusetts |
Entwicklung von neuen gentherapeutika für fibrodysplasia ossificans progressiva
|
|
CN117157108A
(zh)
|
2020-12-29 |
2023-12-01 |
阿库斯股份有限公司 |
用于治疗clrn1相关听力损失和/或视力损失的组合物和方法
|
|
AU2022206197A1
(en)
|
2021-01-05 |
2023-07-13 |
Selecta Biosciences, Inc. |
Viral vector dosing protocols
|
|
TW202242124A
(zh)
|
2021-01-14 |
2022-11-01 |
美商史崔德生物公司 |
靶向t細胞之aav載體
|
|
WO2022159722A1
(en)
|
2021-01-22 |
2022-07-28 |
University Of Massachusetts |
Use of novel mirna-binding site cassettes for antigen-presenting cell detargeting of transgene expression by raav gene therapy vectors
|
|
MX2023008826A
(es)
|
2021-02-01 |
2023-09-15 |
Regenxbio Inc |
Terapia génica para lipofuscinosis neuronal ceroidea.
|
|
US20240316217A1
(en)
|
2021-02-05 |
2024-09-26 |
Regents Of The University Of Minnesota |
Methods for preventing cardiac or skeletal defects in diseases including mucopolysaccharidoses
|
|
AR124981A1
(es)
|
2021-02-26 |
2023-05-24 |
Takeda Pharmaceuticals Co |
Composición y métodos para el tratamiento de la enfermedad de fabry
|
|
CN113549642B
(zh)
*
|
2021-03-02 |
2023-03-07 |
体必康生物科技(广东)股份有限公司 |
一种结核分枝杆菌整合型表达质粒及其应用
|
|
US11760788B2
(en)
|
2021-03-02 |
2023-09-19 |
Pathways Neuro Pharma, Inc. |
Neuroreceptor compositions and methods of use
|
|
CA3212876A1
(en)
|
2021-03-19 |
2022-09-22 |
Adrenas Therapeutics, Inc. |
Gene therapies for 21-hydroxylase deficiency
|
|
WO2022211791A1
(en)
|
2021-03-30 |
2022-10-06 |
AAVnerGene Inc. |
Modified plasma clotting factor viii and method of use thereof
|
|
US11795207B2
(en)
|
2021-03-30 |
2023-10-24 |
AAVnerGene Inc. |
Modified plasma clotting factor VIII and method of use thereof
|
|
EP4323011A1
(de)
|
2021-04-15 |
2024-02-21 |
Spirovant Sciences, Inc. |
Verfahren und zusammensetzungen zur behandlung von zystischer fibrose
|
|
JP2024515626A
(ja)
|
2021-04-16 |
2024-04-10 |
アスクレピオス バイオファーマシューティカル, インコーポレイテッド |
血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドaavビリオン
|
|
WO2022226296A2
(en)
|
2021-04-23 |
2022-10-27 |
University Of Rochester |
Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
|
|
EP4330409A4
(de)
|
2021-04-26 |
2025-04-09 |
University of Massachusetts |
Gentherapien für morbus stargardt (abca4)
|
|
EP4330411B1
(de)
|
2021-04-27 |
2026-03-18 |
4D Molecular Therapeutics Inc. |
Zusammensetzungen und verfahren zur behandlung von augenerkrankungen im zusammenhang mit angiogenese
|
|
TW202309066A
(zh)
|
2021-04-27 |
2023-03-01 |
賓州大學委員會 |
衍生自豬的腺相關病毒衣殼及其用途
|
|
MX2023014008A
(es)
|
2021-05-27 |
2023-12-11 |
Alnylam Pharmaceuticals Inc |
Composiciones y metodos para silenciar la expresion de anhidrasa carbonica 2.
|
|
WO2022258755A1
(en)
|
2021-06-09 |
2022-12-15 |
Universität Duisburg-Essen |
Method for immortalising vesicle-secreting cells
|
|
EP4355766A1
(de)
|
2021-06-14 |
2024-04-24 |
Bridgebio Gene Therapy Research, Inc. |
Gentherapie für tuberöse sklerose
|
|
IL309296A
(en)
|
2021-06-30 |
2024-02-01 |
Alnylam Pharmaceuticals Inc |
Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
|
|
WO2023279108A1
(en)
|
2021-07-01 |
2023-01-05 |
Bridgebio Gene Therapy Research, Inc. |
Gene therapy for galactosemia
|
|
US20250082686A1
(en)
|
2021-07-21 |
2025-03-13 |
Aspen Neuroscience, Inc. |
Aav-based modulation of gba1 and related compositions and uses thereof
|
|
TW202325311A
(zh)
|
2021-08-31 |
2023-07-01 |
美商艾拉倫製藥公司 |
誘導細胞死亡之DFFA樣效應子B (CIDEB) iRNA組合物及其使用方法
|
|
KR20240107201A
(ko)
|
2021-08-31 |
2024-07-08 |
스카우트 바이오, 인코포레이티드 |
항원-결합 분자 및 이의 용도
|
|
US20250288692A1
(en)
|
2021-09-30 |
2025-09-18 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
|
KR20240095539A
(ko)
|
2021-10-08 |
2024-06-25 |
디노 테라퓨틱스, 인코포레이티드 |
캡시드 변이체 및 이의 사용 방법
|
|
US20230140196A1
(en)
|
2021-10-12 |
2023-05-04 |
Selecta Biosciences, Inc. |
Viral vector dosing protocols
|
|
US20230141563A1
(en)
|
2021-10-12 |
2023-05-11 |
Selecta Biosciences, Inc. |
Methods and compositions for attenuating anti-viral transfer vector igm responses
|
|
AU2022366947A1
(en)
|
2021-10-12 |
2024-05-02 |
Bridgebio Gene Therapy Llc |
Methods and compositions for treating leukodystrophies
|
|
WO2023086615A1
(en)
|
2021-11-14 |
2023-05-19 |
Selecta Biosciences, Inc. |
Multiple dosing with viral vectors
|
|
EP4437113A4
(de)
|
2021-11-23 |
2026-04-08 |
Univ Massachusetts |
Gentherapie für spinale muskelatrophie
|
|
KR20240126860A
(ko)
|
2021-11-30 |
2024-08-21 |
재규어 진 테라피, 엘엘씨 |
당뇨병을 치료하기 위한 유전자 요법 방법
|
|
WO2023114816A1
(en)
|
2021-12-14 |
2023-06-22 |
Neurogene, Inc. |
Recombinant optimized galc constructs and methods for treating galc-associated disorders
|
|
AU2022425534A1
(en)
|
2021-12-30 |
2024-07-04 |
Regel Therapeutics, Inc. |
Compositions for modulating expression of sodium voltage-gated channel alpha subunit 1 and uses thereof
|
|
WO2023147383A1
(en)
|
2022-01-25 |
2023-08-03 |
Bridgebio Services Inc. |
Gene therapy for genetic hearing loss
|
|
GB202201242D0
(en)
|
2022-01-31 |
2022-03-16 |
Univ Edinburgh |
Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
|
|
AR128422A1
(es)
|
2022-02-02 |
2024-05-08 |
Akouos Inc |
Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular
|
|
TW202342759A
(zh)
|
2022-02-04 |
2023-11-01 |
美商史崔德生物公司 |
重組腺相關病毒載體及其使用方法
|
|
EP4472657A4
(de)
|
2022-02-04 |
2026-02-18 |
M6P Therapeutics Inc |
Zusammensetzungen und verfahren zur verwendung eines zweipromotorvektors zur behandlung lysosomaler speicherkrankheiten
|
|
US20250179531A1
(en)
|
2022-02-25 |
2025-06-05 |
Vor Biopharma Inc. |
Compositions and methods for homology-directed repair gene modification
|
|
US20230357437A1
(en)
|
2022-03-09 |
2023-11-09 |
Selecta Biosciences, Inc. |
Immunosuppressants in combination with anti-igm agents and related dosing
|
|
EP4504950A1
(de)
|
2022-04-01 |
2025-02-12 |
Takeda Pharmaceutical Company Limited |
Gentherapie für erkrankungen mit zns-manifestationen
|
|
GB202206336D0
(en)
|
2022-04-29 |
2022-06-15 |
Univ Edinburgh |
Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
|
|
US20250382637A1
(en)
|
2022-06-21 |
2025-12-18 |
Regel Therapeutics, Inc. |
Genetic regulatory elements and uses thereof
|
|
WO2024015966A2
(en)
|
2022-07-15 |
2024-01-18 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav having aav clade d and clade e capsids and compositions containing same
|
|
JP2025525583A
(ja)
|
2022-07-19 |
2025-08-05 |
ランパート バイオサイエンス インコーポレイテッド |
非免疫原性環状非ウイルス性dnaベクター
|
|
JP2025526816A
(ja)
|
2022-08-11 |
2025-08-15 |
カーティザン セラピューティクス,インコーポレーテッド |
免疫グロブリンプロテアーゼおよびその融合体に関する組成物および方法
|
|
WO2024047587A1
(en)
|
2022-08-31 |
2024-03-07 |
Regel Therapeutics, Inc. |
Cas-phi compositions and methods of use
|
|
AU2023364350A1
(en)
|
2022-10-19 |
2025-06-05 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
|
WO2024092171A1
(en)
|
2022-10-26 |
2024-05-02 |
University Of Iowa Research Foundation |
Method to deliver large genes using virus and a dna recombination system
|
|
US20260166072A1
(en)
|
2022-11-04 |
2026-06-18 |
Genkardia Inc. |
Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
|
|
EP4619524A1
(de)
|
2022-11-18 |
2025-09-24 |
Genkardia Inc. |
Verfahren und zusammensetzungen zur prävention, behandlung oder umkehrung von diastolischer herzdysfunktion
|
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
|
WO2024124019A2
(en)
|
2022-12-07 |
2024-06-13 |
Ginkgo Bioworks, Inc. |
Aav vectors targeting hematopoietic stem cells
|
|
WO2024129696A1
(en)
|
2022-12-12 |
2024-06-20 |
Retromer Therapeutics Corp. |
Aav and lentiviral constructs comprising a sorl1 mini-gene for use in treating neurodegenerative diseases
|
|
KR20250138783A
(ko)
|
2023-02-01 |
2025-09-22 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
rAAV 생산 방법
|
|
WO2024178386A1
(en)
|
2023-02-24 |
2024-08-29 |
Aarhus Universitet |
Methods of treating endosomal trafficking diseases
|
|
JP2026509271A
(ja)
|
2023-03-10 |
2026-03-17 |
ダイノ セラピューティクス,インコーポレーテッド |
カプシドポリペプチドおよびその使用方法
|
|
US12383615B2
(en)
|
2023-03-23 |
2025-08-12 |
Carbon Biosciences, Inc. |
Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
|
|
WO2024196965A1
(en)
|
2023-03-23 |
2024-09-26 |
Carbon Biosciences, Inc. |
Parvovirus compositions and related methods for gene therapy
|
|
AU2024266138A1
(en)
|
2023-05-03 |
2025-11-13 |
Manifold Biotechnologies, Inc. |
Methods and compositions for high-throughput protein delivery, screening, and detection
|
|
KR20260010739A
(ko)
|
2023-05-11 |
2026-01-21 |
유니버시티 하스피탈즈 클리블랜드 메디컬 센터 |
항불안 치료
|
|
WO2024233791A1
(en)
|
2023-05-11 |
2024-11-14 |
Seelos Therapeutics, Inc. |
Methods of treating neurodegenerative disorders
|
|
AU2024271851A1
(en)
|
2023-05-16 |
2025-12-18 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
|
WO2024241176A1
(en)
|
2023-05-24 |
2024-11-28 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of diseases with central nervous system disorders
|
|
JP2026518475A
(ja)
|
2023-05-26 |
2026-06-08 |
リーゲル セラピューティクス インコーポレイティド |
ナトリウム電位依存性チャネルアルファサブユニット2の発現を調節するための組成物及びその使用
|
|
KR20260082361A
(ko)
|
2023-08-31 |
2026-06-04 |
디노 테라퓨틱스, 인코포레이티드 |
캡시드 폴리펩타이드 및 이의 사용 방법
|
|
CN122438950A
(zh)
|
2023-10-17 |
2026-07-21 |
里格尔医疗股份有限公司 |
用于心肌组织表达的遗传调控元件及其用途
|
|
WO2025117745A1
(en)
|
2023-12-01 |
2025-06-05 |
Caribou Biosciences, Inc. |
Methods and compositions for improving precision of endonuclease-mediated genome editing
|
|
TW202545971A
(zh)
|
2024-02-08 |
2025-12-01 |
美商戴諾治療公司 |
殼體多肽及其使用方法
|
|
WO2025227063A1
(en)
|
2024-04-26 |
2025-10-30 |
Affinia Therapeutics Inc. |
Recombinant aavs with improved tropism and specificity
|
|
WO2025235491A1
(en)
|
2024-05-07 |
2025-11-13 |
Affinia Therapeutics Inc. |
Recombinant aav for treatment of cardiac diseases
|
|
TW202613313A
(zh)
|
2024-05-31 |
2026-04-01 |
美商薩羅塔治療公司 |
肌向性raav
|
|
WO2026020116A1
(en)
|
2024-07-18 |
2026-01-22 |
Massachusetts Institute Of Technology |
Methods and compositions for enriching the production of dna cargo loaded recombinant adeno-associated virus capsids
|
|
WO2026017965A1
(en)
|
2024-07-19 |
2026-01-22 |
The University Court Of The University Of Edinburgh |
Recombinant therapeutic fxn constructs and methods of treating friedreich ataxia and related conditions
|
|
WO2026064428A2
(en)
|
2024-09-18 |
2026-03-26 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2026064442A2
(en)
|
2024-09-18 |
2026-03-26 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2026064444A1
(en)
|
2024-09-18 |
2026-03-26 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2026064736A1
(en)
|
2024-09-23 |
2026-03-26 |
Carbon Biosciences, Inc. |
Parvovirus compositions and related methods for gene therapy
|
|
WO2026064739A1
(en)
|
2024-09-23 |
2026-03-26 |
Carbon Biosciences, Inc. |
Parvovirus compositions and related methods for gene therapy
|
|
WO2026122963A1
(en)
|
2024-12-06 |
2026-06-11 |
Dyno Therapeutics, Inc. |
Capsid polypeptides and methods of use thereof
|
|
WO2026150324A1
(en)
|
2025-01-10 |
2026-07-16 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating dysferlinopathies
|
|
WO2026165374A2
(en)
|
2025-01-31 |
2026-08-06 |
Genzyme Corporation |
Engineered adeno-associated virus capsids
|